Tuesday, August 17, 2021

Here Comes the Boosters

Oh boy. I was standing with Laura and Delaney on a corner in Frankfurt when I realized that things were getting ugly. We were in Germany last week, and right before we got on a flight home, we received an email. We had to get tested for COVID-19 before we flew home. It was a stark reversal of expectations. Remember, we were supposed to be over this pandemic. And – well – it's not a pandemic anymore. It's an endemic. And COVID – by that definition – will be a part of our lives for the foreseeable future. While the United States is cozy and content with the luxury of getting a third shot soon, we are facing dire conditions heading into the fall.
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
 
 
Here Comes the Boosters

Dear Reader,

Oh boy.

I was standing with Laura and Delaney on a corner in Frankfurt when I realized that things were getting ugly. We were in Germany last week, and right before we got on a flight home, we received an email.

We had to get tested for COVID-19 before we flew home. It was a stark reversal of expectations. Remember, we were supposed to be over this pandemic.

And – well – it's not a pandemic anymore. It's an endemic.

And COVID – by that definition – will be a part of our lives for the foreseeable future. While the United States is cozy and content with the luxury of getting a third shot soon, we are facing dire conditions heading into the fall.

This isn't going to slow down. The colder weather will produce new variants. And until we find a way to shut this down, the longer we're going to see big moves in the COVID-19 stocks.

Sponsored Message

Bill Gates and Microsoft just invested $2 billion...

And Elon Musk put a whopping $110 billion into this trend.

One investment analyst calls the company behind this technology "The Next Tesla"...

Watch a demo, and get the name of this company at no charge, when you click here »

Moderna (MRNA) and BioNTech (BNTX) are pure momentum stocks. And the machines are buying them up left and right. There has been little guidance yet around Johnson & Johnson (JNJ) boosters, but the stock is rising higher toward its resistance point of $185.

Me? I like the diagnostic companies. My Surge Point Trader subscribers have enjoyed gains on Co-Diagnostics (CODX). And I think that stock is heading back to $15.00 per share.

My key concern, however, is how bad the fall is for COVID. Schools are returning. Kids are supposed to be in college. Do we really think this is going to work in places across the Midwest, for example?

I think that this is going to be the death knell of schools if they can't get back to campus soon.

Now is the time to invest in e-learning ahead of the fall. Coursera, 2U, and the other virtual stocks are prime buys right now, in my opinion. Get out in front of this ahead of time.

Momentum Check

So, here's another point of interest. S&P 500 momentum went negative today, which is a good reason to gather cash. I'm not sure how long this will last, but I won't make any active buy recommendations for the next 24 hours. Let's stand by and wait for the smoke to clear.

There is still $4.5 trillion in cash on the sidelines. Maybe a nice pullback will put that money to work.

I'll be back to talk about my favorite education stocks in the months ahead.

Enjoy your day,

Garrett Baldwin
Chief Analyst, American Markets

© 2021 Godesburg Financial Publishing, Inc.

DISCLAIMER:

COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) AND EMPLOYEES ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP's communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision.

RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade.

GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations.

GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. GFP, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers.

For more information, please visit our disclaimer page here.


No comments:

Post a Comment

If you’re doing this - beware.

...